Gemfibrozil Tablet
Product Images NDC 71610-601

8 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 71610-601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 600 mg (71610 0601 60)

Bottle Label 600 mg (71610 0601 60)
GEMFIBROZIL 600 mg oral tablets label showing 90 tablets per package. The label states the drug name as Gemfibrozil, USP, with storage instructions and manufacturer information. It is labeled by Aphena Pharma Solutions - Tennessee, LLC, for prescription use only, with a barcode and NDC 71610-0601-60 visible.*
FDA Label Image

Additional Adv Reactions (Additional Adv Reactions)

Additional Adv Reactions (Additional Adv Reactions)
This image displays a side-by-side list of adverse reactions categorized by causal relationship for Gemfibrozil tablets. It differentiates reactions that are probably causally related from those not established, covering various systems such as general, cardiac, gastrointestinal, central nervous, eye, genitourinary, musculoskeletal, clinical laboratory, hematopoietic, immunologic, and integumentary.*
FDA Label Image

Adv Reactions (Adverse Reactions)

Adv Reactions (Adverse Reactions)
A data table comparing the frequency of adverse events in percentage of subjects between GEMFIBROZIL (N=2046) and placebo (N=2035) groups. It lists gastrointestinal reactions, acute appendicitis, atrial fibrillation, and other adverse events with their corresponding frequencies in both groups, highlighting differences in reported side effects.*
FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Struct (Struct Gemfibrozil)

Struct (Struct Gemfibrozil)
Chemical structure of Gemfibrozil showing its molecular composition with aromatic ring, ether linkage, and carboxylic acid group.*
FDA Label Image

Tab 1 (Tab 1)

Tab 1 (Tab  1)
A data table titled 'Table I Reduction in CHD Rates (events per 1000 patients) by Baseline Lipids in the Helsinki Heart Study, Years 0-5,' showing incidence of events in different patient groups. Columns compare placebo (P) and gemfibrozil (G) groups across lipid categories, with differences in event rates reported, involving fatal and nonfatal myocardial infarctions plus sudden cardiac deaths.*
FDA Label Image

Tab 2 (Tab 2)

Tab 2 (Tab  2)
A data table titled 'Table II' showing cardiac events and all-cause mortality rates (events per 1000 patients) over a 3.5-year open-label follow-up to the Helsinki Heart Study. It lists six groups based on original randomization and drug taken during follow-up, with numerical values for cardiac events and all-cause mortality for each group.*
FDA Label Image

Tab 3 (Tab 3)

Tab 3 (Tab  3)
A data table titled 'Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality in the Helsinki Heart Study, Years 0-8.5' comparing numbers and hazard ratios for gemfibrozil versus placebo groups. The table provides event counts at study start, hazard ratios, and confidence intervals for cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality in a clinical study setting.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.